Bod Australia Limited announced that it has secured Clinical Trial Authorisation from the United Kingdom's Medicines & Healthcare Products Regulatory Agency ("MHRA") to commence an open label clinical trial in association with Drug Science UK to explore the effectiveness of Bod's medicinal cannabis product, MediCabilis® 5% ("MediCabilis®") on symptoms associated with the long term impact of SARS-CoV-2 ("COVID-19"), commonly referred to as long-COVID. This initiative provides Bod with an important opportunity to build on the growing body of evidence for the use of MediCabilis®, as well as insight into the potential use of the product as a treatment against long-COVID. Upon completion of the trial and pending successful results, Bod will embark on the commercialisation of a MediCabilis® product which can be used to treat the condition.

The Company anticipates that this will lead to increased sales volumes across the UK and other territories. Long-COVID is an emerging condition referring to persistent or new symptoms that develop at least eight weeks following an initial COVID-19 infection. Long-COVID may include the continuation of symptoms from when an individual is first infected, or new symptoms where individuals feel they have improved and a month after being infected symptoms arise again.

Under the clinical trial setting, recruits will be administered Bod's medicinal cannabis product, MediCabilis®,on a daily basis, over a six-month period. Each participant will undertake monthly and daily self-reporting assessing common long-COVID symptoms such as breathlessness, fatigue, cognition and pain via a smartphone app. The collective results will determine the feasibility of medicinal cannabis and MediCabilis® in the treatment of the condition and whether it is safe to use.